OAJ
SRNE

Ogorek Anthony Joseph’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ogorek Anthony Joseph’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,600
Closed – – 306
2023
Q4 		$0 Hold
3,600
– – ﹤0.01% 302
2023
Q3 		$0 Hold
3,600
– – ﹤0.01% 288
2023
Q2 		$1K Hold
3,600
– – ﹤0.01% 256
2023
Q1 		$1K Hold
3,600
– – ﹤0.01% 264
2022
Q4 		$3K Hold
3,600
– – ﹤0.01% 205
2022
Q3 		$5K Hold
3,600
– – ﹤0.01% 181
2022
Q2 		$7K Hold
3,600
– – ﹤0.01% 175
2022
Q1 		$8K Hold
3,600
– – ﹤0.01% 188
2021
Q4 		$16K Hold
3,600
– – 0.01% 154
2021
Q3 		$27K Hold
3,600
– – 0.01% 104
2021
Q2 		$34K Hold
3,600
– – 0.02% 91
2021
Q1 		$29K Hold
3,600
– – 0.01% 90
2020
Q4 		$24K Buy
+3,600
New +$28.9K 0.01% 86

Other funds holding SRNE

LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return

Ogorek Anthony Joseph's SRNE Position: Q1 2024 in Review

Ogorek Anthony Joseph sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2024, closing a stake of 3,600 shares.

Ogorek Anthony Joseph first reported a position in SRNE in Q4 2020 and held it in 13 quarters. The position peaked at $34K in Q2 2021. 7 funds tracked by Wall St. Rank hold SRNE as of Q1 2024.

  • Ogorek Anthony Joseph reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Ogorek Anthony Joseph sold 3,600 Sorrento Therapeutics, Inc. shares in Q1 2024.
  • Ogorek Anthony Joseph first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 13 quarters.
  • Ogorek Anthony Joseph's Sorrento Therapeutics, Inc. position peaked at $34K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2024.

Based on Ogorek Anthony Joseph's 13F filing for Q1 2024, filed 3 May 2024.